Takeda Has Lymphoma Drug In Final-stage Trials
This article was originally published in PharmAsia News
Executive SummaryTakeda Pharmaceutical says Phase III trials in three major venues indicate the company could file for approval of its lymphoma drug by mid-2011
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.